Doctors state that this drug by Novartis, which doesn’t have any name yet is like that breakthrough therapy which would save more than 3 million Americans and more than 12 million people all over the globe.
Dr. Clyde Yancy, the former American Heart Association President and Cardiology Chief at Northwestern University in Chicago said that this was a new day for the patients.
Further, it was said that it has been a decade now since there was a breakthrough of this magnitude. Nearly 8,500 people were involved in 47 countries and this was the largest experiment that was done in heart failure. Novartis, which is based in Basel, Switzerland designed and partly run it.
The study was stopped in April, 7 months earlier than planned, when there was a clarity that the drug was better than the older one. During this 27 month study, the chances of death due to heart related causes were cut by 20 percent. Also, the risk of hospitalization was reduced by 21 percent.
Results were out at a European Society of Cardiology Conference in Barcelona on Saturday and were published by New England Journal of Medicine. Approval will be sought for the drug by this year end in the U.S and in Europe, early next year.
Heart failure is the main reason for hospitalization of older people, which further leads to death. It develops when weakening of heart muscles is seen over a period of time and there is no effective pumping, often due to damage from heart attack. Fluid backs up into the lungs and people are left gasping for breath.